Advanced

Cystatin C Levels are Positively Correlated with both A beta(42) and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls

Sundelof, Johan; Luoto, Johannes LU ; Hansson, Oskar LU ; Eriksdotter-Jonhagen, Maria; Giedraitis, Vilmantas; Larsson, Anders; Degerman-Gunnarsson, Malin; Ingelsson, Martin; Minthon, Lennart LU and Blennow, Kaj, et al. (2010) In Journal of Alzheimer's Disease 21(2). p.471-478
Abstract
Cystatin C is suggested to be involved in neurodegeneration and the development of Alzheimer's disease (AD) by binding to soluble amyloid-beta (A beta) peptides. Studies of cystatin C levels in cerebrospinal fluid (CSF) in relation to risk of AD are conflicting and relations between cystatin C, A beta(42), and tau levels in CSF in AD, mild cognitive impairment (MCI), and healthy controls are unknown. The objective of this study was to investigate cystatin C, A beta(42), and tau levels in CSF in AD, MCI, and controls. As a secondary aim, the relationships between cystatin C, A beta(42), and tau levels across disease groups were investigated. Cystatin C, A beta(42), total tau, and phosphorylated tau levels in CSF were analyzed by... (More)
Cystatin C is suggested to be involved in neurodegeneration and the development of Alzheimer's disease (AD) by binding to soluble amyloid-beta (A beta) peptides. Studies of cystatin C levels in cerebrospinal fluid (CSF) in relation to risk of AD are conflicting and relations between cystatin C, A beta(42), and tau levels in CSF in AD, mild cognitive impairment (MCI), and healthy controls are unknown. The objective of this study was to investigate cystatin C, A beta(42), and tau levels in CSF in AD, MCI, and controls. As a secondary aim, the relationships between cystatin C, A beta(42), and tau levels across disease groups were investigated. Cystatin C, A beta(42), total tau, and phosphorylated tau levels in CSF were analyzed by turbidimetry (cystatin C) and xMAP Luminex technology (A beta and tau) in persons with AD (n = 101), MCI (n = 84), and healthy control subjects (n = 28). Mean cystatin C levels were similar in cases of AD (5.6 mu mol/L +/- 1.7), MCI (5.4 mu mol/L +/- 1.48), and controls (5.6 mu mol/L +/- 1.6). However, CSF cystatin C levels were strongly and positively correlated with total tau and phosphorylated tau levels (r = 0.61-0.81, p < 0.0001) and A beta(42) (r = 0.35-0.65, p < 0.001) independent of age, gender, and APOE genotype. Mean CSF cystatin C levels did not differ between patients with AD and MCI and healthy controls. Interestingly, cystatin C levels were positively correlated with both tau and A beta(42) levels in CSF independent of age, gender, and APOE genotype. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
epidemiology, cystatin C, case control study, Alzheimer's disease, biomarkers, risk factor
in
Journal of Alzheimer's Disease
volume
21
issue
2
pages
471 - 478
publisher
IOS Press
external identifiers
  • wos:000281887600013
  • scopus:77957352489
ISSN
1387-2877
DOI
10.3233/JAD-2010-091594
language
English
LU publication?
yes
id
b7f47be6-82a7-4447-a117-ec91e2748646 (old id 1697389)
date added to LUP
2010-10-25 09:22:05
date last changed
2018-07-15 03:11:00
@article{b7f47be6-82a7-4447-a117-ec91e2748646,
  abstract     = {Cystatin C is suggested to be involved in neurodegeneration and the development of Alzheimer's disease (AD) by binding to soluble amyloid-beta (A beta) peptides. Studies of cystatin C levels in cerebrospinal fluid (CSF) in relation to risk of AD are conflicting and relations between cystatin C, A beta(42), and tau levels in CSF in AD, mild cognitive impairment (MCI), and healthy controls are unknown. The objective of this study was to investigate cystatin C, A beta(42), and tau levels in CSF in AD, MCI, and controls. As a secondary aim, the relationships between cystatin C, A beta(42), and tau levels across disease groups were investigated. Cystatin C, A beta(42), total tau, and phosphorylated tau levels in CSF were analyzed by turbidimetry (cystatin C) and xMAP Luminex technology (A beta and tau) in persons with AD (n = 101), MCI (n = 84), and healthy control subjects (n = 28). Mean cystatin C levels were similar in cases of AD (5.6 mu mol/L +/- 1.7), MCI (5.4 mu mol/L +/- 1.48), and controls (5.6 mu mol/L +/- 1.6). However, CSF cystatin C levels were strongly and positively correlated with total tau and phosphorylated tau levels (r = 0.61-0.81, p &lt; 0.0001) and A beta(42) (r = 0.35-0.65, p &lt; 0.001) independent of age, gender, and APOE genotype. Mean CSF cystatin C levels did not differ between patients with AD and MCI and healthy controls. Interestingly, cystatin C levels were positively correlated with both tau and A beta(42) levels in CSF independent of age, gender, and APOE genotype.},
  author       = {Sundelof, Johan and Luoto, Johannes and Hansson, Oskar and Eriksdotter-Jonhagen, Maria and Giedraitis, Vilmantas and Larsson, Anders and Degerman-Gunnarsson, Malin and Ingelsson, Martin and Minthon, Lennart and Blennow, Kaj and Kilander, Lena and Basun, Hans and Lannfelt, Lars},
  issn         = {1387-2877},
  keyword      = {epidemiology,cystatin C,case control study,Alzheimer's disease,biomarkers,risk factor},
  language     = {eng},
  number       = {2},
  pages        = {471--478},
  publisher    = {IOS Press},
  series       = {Journal of Alzheimer's Disease},
  title        = {Cystatin C Levels are Positively Correlated with both A beta(42) and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls},
  url          = {http://dx.doi.org/10.3233/JAD-2010-091594},
  volume       = {21},
  year         = {2010},
}